Current status of excision repair cross complementing-group 1 (ERCC1) in cancer
L Gossage, S Madhusudan - Cancer treatment reviews, 2007 - Elsevier
Cisplatin, carboplatin and oxaliplatin are some of the most widely used anti-cancer agents in
solid tumours. The cytotoxicity of platinating agents is directly related to their ability to cause …
solid tumours. The cytotoxicity of platinating agents is directly related to their ability to cause …
Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer
X Wu, J Gu, TT Wu, SG Swisher, Z Liao… - Journal of clinical …, 2006 - ascopubs.org
Purpose Understanding how specific genetic variants modify drug action pathways may
provide informative blueprints for individualized chemotherapy. Methods We applied a …
provide informative blueprints for individualized chemotherapy. Methods We applied a …
ERCC1 expression as a molecular marker of cisplatin resistance in human cervical tumor cells
RA Britten, D Liu, A Tessier… - … journal of cancer, 2000 - Wiley Online Library
Cisplatin is a valuable adjuvant to radiotherapy for the treatment of cervical cancer. Because
the advantage of combining cisplatin with radiotherapy is likely to be attributable to additive …
the advantage of combining cisplatin with radiotherapy is likely to be attributable to additive …
Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX–bevacizumab or FOLFIRI–bevacizumab: results …
JC Bendell, TS Bekaii-Saab, AL Cohn… - The …, 2012 - academic.oup.com
Abstract Background. The Avastin® Registry: Investigation of Effectiveness and Safety
(ARIES) study is a prospective, community-based observational cohort study that evaluated …
(ARIES) study is a prospective, community-based observational cohort study that evaluated …
[HTML][HTML] ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation
HJ Jun, MJ Ahn, HS Kim, SY Yi, J Han, SK Lee… - British journal of …, 2008 - nature.com
The excision repair cross-complementation group 1 (ERCC1) enzyme plays a rate-limiting
role in the nucleotide excision repair pathway and is associated with resistance to platinum …
role in the nucleotide excision repair pathway and is associated with resistance to platinum …
Early Metabolic Response Evaluation by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography Allows In vivo Testing of Chemosensitivity in Gastric …
Purpose: We prospectively evaluated the predictive value of positron emission tomography
using fluorine-18 fluorodeoxyglucose (FDG-PET) for in vivo testing of chemosensitivity in …
using fluorine-18 fluorodeoxyglucose (FDG-PET) for in vivo testing of chemosensitivity in …
A synthetic suicide riboswitch for the high-throughput screening of metabolite production in Saccharomyces cerevisiae
Artificial devices such as the synthetic riboswitch have shown potential to introduce
unnatural phenotypic perturbation because its synthetic traits are distinct from that of innate …
unnatural phenotypic perturbation because its synthetic traits are distinct from that of innate …
Genetic polymorphisms and treatment response in advanced non-small cell lung cancer
D Su, S Ma, P Liu, Z Jiang, W Lv, Y Zhang, Q Deng… - Lung cancer, 2007 - Elsevier
BACKGROUND: Genetic polymorphisms involved in DNA repair and apoptosis are
suspected to influence patient response to cancer treatment. To evaluate the effect of …
suspected to influence patient response to cancer treatment. To evaluate the effect of …
Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based …
S Ota, G Ishii, K Goto, K Kubota, YH Kim, M Kojika… - Lung cancer, 2009 - Elsevier
PURPOSE: The aim of this study was to determine the prognostic value of expression of ATP
binding cassette (ABC) transporter proteins and DNA repair gene proteins by …
binding cassette (ABC) transporter proteins and DNA repair gene proteins by …
The paradigm of mutant p53-expressing cancer stem cells and drug resistance
Y Shetzer, H Solomon, G Koifman… - …, 2014 - academic.oup.com
It is well accepted that expression of mutant p53 involves the gain of oncogenic-specific
activities accentuating the malignant phenotype. Depending on the specific cancer type …
activities accentuating the malignant phenotype. Depending on the specific cancer type …